Glioblastoma multiforme in patients with human immunodeficiency virus: an integrated review and analysis.
Antiretroviral therapy
Cancer
GBM
Glioblastoma
HIV
PLWH
Journal
Journal of neuro-oncology
ISSN: 1573-7373
Titre abrégé: J Neurooncol
Pays: United States
ID NLM: 8309335
Informations de publication
Date de publication:
Sep 2022
Sep 2022
Historique:
received:
14
06
2022
accepted:
09
07
2022
pubmed:
21
7
2022
medline:
20
9
2022
entrez:
20
7
2022
Statut:
ppublish
Résumé
As lifespans for persons living with HIV (PLWH) have improved over the last decade, there has been a simultaneous increase in non-AIDS-related cancer in that group. However, there is a paucity of data regarding the incidence of glioblastoma multiforme (GBM) in PLWH. Better understanding of the oncogenesis, natural history, and treatment outcomes of GBM in PLWH should lead to improved treatment strategies. We performed a comprehensive literature search of six electronic databases to identify eligible cases of GBM among PLWH. Kaplan-Meier estimates, Fisher's exact test, and logistic regression were used to interrogate the data. Epidemiologic data on global HIV prevalence was obtained from the 2016 UNAIDS incidence report, and CNS cancer incidence was obtained from the GDB 2016 Brain and Other CNS Cancer Collaborators. There is an inverse relationship between the incidence of HIV and CNS cancer globally. Median overall survival (OS) from GBM diagnosis was 8 months. Estimates for survival at 1 and 2 years were 28 and 5%, respectively. There were no statistically significant predictors of OS in this setting. There was a significant difference (p < 0.01) in OS in PLWH and GBM when compared to TCGA age matched cohorts. The diagnosis of GBM in PLWH is severely underreported in the literature. Despite maximal treatment, OS in this patient population is significantly less than in HIV-negative people. There was a poor prognosis of GBM in PLWH, which is inconsistent with previous reports. Further investigation is required for PLWH and concomitant GBM. Analyses must consider if HAART is maintained in PLWH during GBM treatment.
Identifiants
pubmed: 35857248
doi: 10.1007/s11060-022-04095-4
pii: 10.1007/s11060-022-04095-4
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
571-579Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Centers for Disease, C. (1981) Pneumocystis pneumonia–Los Angeles. MMWR Morb Mortal Wkly Rep 30(21):250–252
Centers for Disease, C. (1981) Kaposi’s sarcoma and Pneumocystis pneumonia among homosexual men–New York City and California. MMWR Morb Mortal Wkly Rep 30(25):305–308
Hernandez-Ramirez RU et al (2017) Cancer risk in HIV-infected people in the USA from 1996 to 2012: a population-based, registry-linkage study. Lancet HIV 4(11):e495–e504
pubmed: 28803888
pmcid: 5669995
doi: 10.1016/S2352-3018(17)30125-X
Shmakova A, Germini D, Vassetzky Y (2020) HIV-1, HAART and cancer: a complex relationship. Int J Cancer 146(10):2666–2679
pubmed: 31603989
doi: 10.1002/ijc.32730
Ji Y, Lu H (2017) Malignancies in HIV-Infected and AIDS patients. Adv Exp Med Biol 1018:167–179
pubmed: 29052137
doi: 10.1007/978-981-10-5765-6_10
Rock K et al (2012) A clinical review of treatment outcomes in glioblastoma multiforme–the validation in a non-trial population of the results of a randomised Phase III clinical trial: has a more radical approach improved survival? Br J Radiol 85(1017):e729–e733
pubmed: 22215883
pmcid: 3487092
doi: 10.1259/bjr/83796755
Birol Sarica F et al (2010) Effectiveness of temozolomide treatment used at the same time with radiotherapy and adjuvant temozolomide; concomitant therapy of glioblastoma multiforme: multivariate analysis and other prognostic factors. J Neurosurg Sci 54(1):7–19
pubmed: 20436394
Chaudhry NS et al (2013) Predictors of long-term survival in patients with glioblastoma multiforme: advancements from the last quarter century. Cancer Invest 31(5):287–308
pubmed: 23614654
doi: 10.3109/07357907.2013.789899
Blumenthal DT et al (1999) Primary intracranial neoplasms in patients with HIV. Neurology 52(8):1648–1651
pubmed: 10331693
doi: 10.1212/WNL.52.8.1648
Hall JR, Short SC (2009) Management of glioblastoma multiforme in HIV patients: a case series and review of published studies. Clin Oncol (R Coll Radiol) 21(8):591–597
doi: 10.1016/j.clon.2009.04.006
Jokonya L et al (2018) Prevalence of human immunodeficiency virus infection in brain glioma patients: Is the virus protective from gliomas? Surg Neurol Int 9:103
pubmed: 29930869
pmcid: 5991276
doi: 10.4103/sni.sni_423_17
Choy W et al (2016) Impact of human immunodeficiency virus in the pathogenesis and outcome of patients with glioblastoma multiforme. Brain Tumor Res Treat 4(2):77–86
pubmed: 27867916
pmcid: 5114196
doi: 10.14791/btrt.2016.4.2.77
Moher D et al (2010) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 8(5):336–341
pubmed: 20171303
doi: 10.1016/j.ijsu.2010.02.007
Robbins HA et al (2015) Excess cancers among HIV-infected people in the United States. J Natl Cancer Inst. https://doi.org/10.1093/jnci/dju503
doi: 10.1093/jnci/dju503
pubmed: 25663691
pmcid: 4334816
Hart BB et al (2018) Inflammation-related morbidity and mortality among hiv-positive adults: how extensive is it? J Acquir Immune Defic Syndr 77(1):1–7
pubmed: 28991883
pmcid: 5720921
doi: 10.1097/QAI.0000000000001554
Isaguliants M et al (2021) Oncogenic effects of HIV-1 proteins. Mech Behind. Cancers (Basel) 13(2):305
doi: 10.3390/cancers13020305
Coghill AE et al (2018) Risk of Breast, Prostate, and Colorectal Cancer Diagnoses Among HIV-Infected Individuals in the United States. J Natl Cancer Inst 110(9):959–966
pubmed: 29529223
pmcid: 6136931
doi: 10.1093/jnci/djy010
Ghosn J et al (2018) Hiv. Lancet 392(10148):685–697
pubmed: 30049419
doi: 10.1016/S0140-6736(18)31311-4
Brain GBD, Other CNSCC (2019) Global, regional, and national burden of brain and other CNS cancer, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 18(4):376–393
doi: 10.1016/S1474-4422(18)30468-X
Lutgen V et al (2020) HIV infects astrocytes in vivo and egresses from the brain to the periphery. PLoS Pathog 16(6):e1008381
pubmed: 32525948
pmcid: 7289344
doi: 10.1371/journal.ppat.1008381
Moulignier A et al (1994) Cerebral glial tumors and human immunodeficiency virus-1 infection. More than a coincidental association Cancer 74(2):686–692
pubmed: 8033048
Vincendeau M et al (2010) Control of HIV replication in astrocytes by a family of highly conserved host proteins with a common Rev-interacting domain (Risp). AIDS 24(16):2433–2442
pubmed: 20827171
doi: 10.1097/QAD.0b013e32833e8758
Caccuri F et al (2012) HIV-1 matrix protein p17 promotes angiogenesis via chemokine receptors CXCR1 and CXCR2. Proc Natl Acad Sci U S A 109(36):14580–14585
pubmed: 22904195
pmcid: 3437870
doi: 10.1073/pnas.1206605109
Sharma I et al (2018) IL-8/CXCR1/2 signalling promotes tumor cell proliferation, invasion and vascular mimicry in glioblastoma. J Biomed Sci 25(1):62
pubmed: 30086759
pmcid: 6081798
doi: 10.1186/s12929-018-0464-y
Scheidegger P et al (2001) Signalling properties of an HIV-encoded angiogenic peptide mimicking vascular endothelial growth factor activity. Biochem J 353(Pt 3):569–578
pubmed: 11171054
pmcid: 1221603
doi: 10.1042/bj3530569
Behnan J, Finocchiaro G, Hanna G (2019) The landscape of the mesenchymal signature in brain tumours. Brain 142(4):847–866
pubmed: 30946477
pmcid: 6485274
doi: 10.1093/brain/awz044
Bhat KPL et al (2013) Mesenchymal differentiation mediated by NF-kappaB promotes radiation resistance in glioblastoma. Cancer Cell 24(3):331–346
pubmed: 23993863
doi: 10.1016/j.ccr.2013.08.001
Iwadate Y (2016) Epithelial-mesenchymal transition in glioblastoma progression. Oncol Lett 11(3):1615–1620
pubmed: 26998052
pmcid: 4774466
doi: 10.3892/ol.2016.4113
Kalluri R, Weinberg RA (2009) The basics of epithelial-mesenchymal transition. J Clin Invest 119(6):1420–1428
pubmed: 19487818
pmcid: 2689101
doi: 10.1172/JCI39104
Zeisberg M, Neilson EG (2009) Biomarkers for epithelial-mesenchymal transitions. J Clin Invest 119(6):1429–1437
pubmed: 19487819
pmcid: 2689132
doi: 10.1172/JCI36183
Lien K et al (2019) HIV-1 proteins gp120 and tat induce the epithelial-mesenchymal transition in oral and genital mucosal epithelial cells. PLoS ONE 14(12):e0226343
pubmed: 31869348
pmcid: 6927651
doi: 10.1371/journal.pone.0226343
Bayurova E et al (2019) HIV-1 reverse transcriptase promotes tumor growth and metastasis formation via ROS-dependent upregulation of twist. Oxid Med Cell Longev 2019:6016278
pubmed: 31885806
pmcid: 6915010
doi: 10.1155/2019/6016278
Rich JN (2003) The role of transforming growth factor-beta in primary brain tumors. Front Biosci 8:e245–e260
pubmed: 12456378
doi: 10.2741/992
Bruna A et al (2007) High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. Cancer Cell 11(2):147–160
pubmed: 17292826
doi: 10.1016/j.ccr.2006.11.023
Penuelas S et al (2009) TGF-beta increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma. Cancer Cell 15(4):315–327
pubmed: 19345330
doi: 10.1016/j.ccr.2009.02.011
Valentin-Guillama G et al (2018) HIV-1 envelope protein gp120 promotes proliferation and the activation of glycolysis in glioma cell. Cancers (Basel). 10(9):301
pmcid: 6162763
doi: 10.3390/cancers10090301
Bethel-Brown C et al (2011) HIV-1 Tat-mediated induction of platelet-derived growth factor in astrocytes: role of early growth response gene 1. J Immunol 186(7):4119–4129
pubmed: 21368226
doi: 10.4049/jimmunol.1002235
Mischel PS, Cloughesy TF (2003) Targeted molecular therapy of GBM. Brain Pathol 13(1):52–61
pubmed: 12580545
doi: 10.1111/j.1750-3639.2003.tb00006.x
Djuzenova CS et al (2015) Actin cytoskeleton organization, cell surface modification and invasion rate of 5 glioblastoma cell lines differing in PTEN and p53 status. Exp Cell Res 330(2):346–357
pubmed: 25149900
doi: 10.1016/j.yexcr.2014.08.013
Zheng H et al (2008) p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature 455(7216):1129–1133
pubmed: 18948956
pmcid: 4051433
doi: 10.1038/nature07443
Greenway AL et al (2002) Human immunodeficiency virus type 1 Nef binds to tumor suppressor p53 and protects cells against p53-mediated apoptosis. J Virol 76(6):2692–2702
pubmed: 11861836
pmcid: 135999
doi: 10.1128/JVI.76.6.2692-2702.2002
Santerre M et al (2019) HIV-1 Nef promotes cell proliferation and microRNA dysregulation in lung cells. Cell Cycle 18(2):130–142
pubmed: 30563405
pmcid: 6343720
doi: 10.1080/15384101.2018.1557487
Kramer-Hammerle S et al (2001) HIV type 1 Nef promotes neoplastic transformation of immortalized neural cells. AIDS Res Hum Retrovir 17(7):597–602
pubmed: 11375055
doi: 10.1089/088922201300119699
Hajjar M et al (1992) Non-acquired immune deficiency syndrome-defining malignancies in a hospital-based cohort of human immunodeficiency virus-infected patients: Bordeaux, France, 1985–1991 Groupe d’Epidemiologie Clinique du SIDA en Aquitaine. J Natl Cancer Inst 84(20):1593–1595
pubmed: 1404453
doi: 10.1093/jnci/84.20.1593
Cobucci RN et al (2015) Assessing the impact of HAART on the incidence of defining and non-defining AIDS cancers among patients with HIV/AIDS: a systematic review. J Infect Public Health 8(1):1–10
pubmed: 25294086
doi: 10.1016/j.jiph.2014.08.003
Leone S et al (2011) Causes of death and risk factors among HIV-infected persons in the HAART era: analysis of a large urban cohort. Infection 39(1):13–20
pubmed: 21246246
doi: 10.1007/s15010-010-0079-z
Spataro V, Norbury C, Harris AL (1998) The ubiquitin-proteasome pathway in cancer. Br J Cancer 77(3):448–455
pubmed: 9472642
pmcid: 2151296
doi: 10.1038/bjc.1998.71
Kato GJ (1999) Human genetic diseases of proteolysis. Hum Mutat 13(2):87–98
pubmed: 10094566
doi: 10.1002/(SICI)1098-1004(1999)13:2<87::AID-HUMU1>3.0.CO;2-K
Kudo Y et al (2000) p27Kip1 accumulation by inhibition of proteasome function induces apoptosis in oral squamous cell carcinoma cells. Clin Cancer Res 6(3):916–923
pubmed: 10741716
Laurent N et al (2004) Effects of the proteasome inhibitor ritonavir on glioma growth in vitro and in vivo. Mol Cancer Ther 3(2):129–136
pubmed: 14985453
doi: 10.1158/1535-7163.129.3.2
Pyrko P et al (2007) HIV-1 protease inhibitors nelfinavir and atazanavir induce malignant glioma death by triggering endoplasmic reticulum stress. Cancer Res 67(22):10920–10928
pubmed: 18006837
doi: 10.1158/0008-5472.CAN-07-0796
Pore N et al (2006) HIV protease inhibitors decrease VEGF/HIF-1alpha expression and angiogenesis in glioblastoma cells. Neoplasia 8(11):889–895
pubmed: 17132220
pmcid: 1716015
doi: 10.1593/neo.06535
Vaccher E et al (2001) Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma. Cancer 91(1):155–163
pubmed: 11148572
doi: 10.1002/1097-0142(20010101)91:1<155::AID-CNCR20>3.0.CO;2-B
“Global HIV & AIDS Statistics - Fact Sheet.” Edited by UNAIDS, UNAIDS, 2021 https://www.unaids.org/en/resources/fact-sheet .
Cedeno-Laurent F, Trujillo JR (2011) Gliomas and brain lymphomas in HIV-1/AIDS patients: reflections from a 20-year follow up in Mexico and Brazil. Microbiology Research 2(1):e11. https://doi.org/10.4081/mr.2011.e11
doi: 10.4081/mr.2011.e11